Abstract
216 Approved drug lubiprostone is not a selective chloride channel-2 activator, and its prosecretory effect primarily depends on cystic fibrosis transmembrane conductance regulator in human intestinal epithelial cells
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Paper Title
Journal
Date
